Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial |
| |
| Affiliation: | 1. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran, Iran;2. Department of Endocrinology, Tehran University of Medical Sciences, Tehran, Iran;3. Department of Pharmacotherapy, School of Pharmacy, Shiraz University of Medical Sciences, P.O. Box 1583, Shiraz, Iran;4. University Hospital Center Zagreb, Department of Internal medicine, University of Zagreb School of Medicine, Kišpatićeva 12, Zagreb, Croatia;5. Sabinsa Corporation, East Windsor, NJ, United States;6. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;1. Department of Biology, National Autonomous University of Mexico (UNAM), Mexico City, Mexico;2. Department of Nephrology, National Institute of Cardiology “Ignacio Chávez”, Mexico City, Mexico;1. Faculty Research Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, UK;2. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran;3. Students'' Scientific Research Center (SSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran;4. Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research center, Isfahan University of Medical Sciences, Isfahan, Iran;5. Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran;6. Halal Research Center of IRI, FDA, Tehran, Iran;1. Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran;2. National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran;3. Department of Nutrition, Khalkhal University of Medical Sciences, Khalkhal, Iran;4. Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran;5. Proteomics Research Center and Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran;6. National Nutrition and Food Technology Research Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran;7. Student Research Committee, Babol University of Medical Sciences, Babol, Iran;1. College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates;2. Consumer Product Safety Section, Public Health and Safety Department, Dubai Municipality, United Arab Emirates;1. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;2. Department of Endocrinology, Baqiyatallah University of Medical Sciences, Tehran, Iran;3. Neurogenic Inflammation Research Center, Department of Modern Sciences and Technologies, Mashhad University of Medical Sciences, Mashhad, Iran;4. Sabinsa Inc., Princeton, NJ, USA;5. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;6. Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia |
| |
| Abstract: | BackgroundType 2 diabetes (T2D) is an established risk factor for cardiovascular disease (CVD) and is associated with disturbed metabolism of lipids and lipoproteins. Curcuminoids are natural products with anti-diabetic and lipid-modifying actions but their efficacy in improving dyslipidemia in diabetic individuals has not been sufficiently studied.ObjectiveTo investigate the efficacy of supplementation with curcuminoids, plus piperine as an absorption enhancer, in improving serum lipids in patients with T2D.MethodsIn this 12-week randomized double-blind placebo-controlled trial, subjects with T2D (n = 118) were assigned to curcuminoids (1000 mg/day plus piperine 10 mg/day) or placebo plus standard of care for T2D. Serum concentrations of lipids including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], and non-HDL-C were determined at baseline and at the end of trial.ResultsBetween-group comparison of change in the study parameters revealed significant reductions in serum levels of TC (−21.86 ± 25.78 versus −17.06 ± 41.51, respectively; p = 0.023), non-HDL-C (−23.42 ± 25.13 versus −16.84 ± 41.42, respectively; p = 0.014) and Lp(a) (−1.50 ± 1.61 versus −0.34 ± 1.73, respectively; p = 0.001) and elevations in serum HDL-C levels (1.56 ± 4.25 versus −0.22 ± 4.62, respectively; p = 0.048) in the curcuminoids group as compared with the placebo group (p < 0.05). Serum TG and LDL-C changes did not show any significant difference between the study groups (p > 0.05).ConclusionCurcuminoids supplementation can reduce serum levels of atherogenic lipid indices including non-HDL-C and Lp(a). Therefore, curcuminoids supplementation could contribute to a reduced risk of cardiovascular events in dyslipidemic patients with T2D. |
| |
| Keywords: | Curcumin Diabetes Cardiovascular disease Cholesterol Dyslipidemia Lipoprotein(a) |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
